Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple System Atrophy (MSA) Clear all
No Longer Available No phase listed Expanded access

Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)

NCT05086094
View directory record Official record
Conditions
Multiple System Atrophy (MSA)
Interventions
BHV3241, verdiperstat
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

NCT02705755
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension
Interventions
TD-9855, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
40 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Long Beach, California • Farmington Hills, Michigan • Berlin, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Results available

Study of BHV-3241 in Participants With Multiple System Atrophy

NCT03952806
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Verdiperstat, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
29
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jul 22, 2026, 6:40 PM EDT
Not listed No phase listed Observational

Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders

NCT05486806
View directory record Official record
Conditions
Neurodegenerative Diseases, sca3, MSA - Multiple System Atrophy, Ataxia, Synucleinopathies
Interventions
18F-PBR06, 18F-PBR06
Drug · Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Jul 22, 2026, 6:40 PM EDT
Active, not recruiting Phase 1 Interventional

GDNF Gene Therapy for Multiple System Atrophy

NCT04680065
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
AAV2-GDNF gene therapy, Sham (Placebo) Surgery
Biological · Procedure
Lead sponsor
Brain Neurotherapy Bio, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 22, 2026, 6:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The CurePSP Genetics Program

NCT06647641
View directory record Official record
Conditions
PSP, PSP - Progressive Supranuclear Palsy, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration Syndrome, Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), MSA, MSA - Multiple System Atrophy, MSA-C, Multiple System Atrophy, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, Cerebellar Type, Multiple System Atrophy, Parkinsonian Type, Progressive Supranuclear Palsy, Progressive Supranuclear Palsy(PSP), Progressive Supranuclear Palsy (PSP)
Interventions
Whole genome sequencing will be performed at the NIH
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jul 22, 2026, 6:40 PM EDT
Active, not recruiting No phase listed Observational

Remote Monitoring in Progressive Supranuclear Palsy (PSP)

NCT04753320
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Parkinson Disease, MSA - Multiple System Atrophy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Jul 22, 2026, 6:40 PM EDT
Recruiting No phase listed Observational

Multiple System Atrophy Multidisciplinary Clinic

NCT03811808
View directory record Official record
Conditions
Multiple System Atrophy (MSA)
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 6:40 PM EDT
Recruiting Phase 2 Interventional

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

NCT06868628
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Foralumab Nasal
Drug
Lead sponsor
Tiziana Life Sciences LTD
Industry
Eligibility
30 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 6:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

NCT06706622
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Amlenetug, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
40 Years to 75 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
23
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 6:40 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT03829657
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
Interventions
ampreloxetine, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Sun City, Arizona • La Jolla, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Jul 22, 2026, 6:40 PM EDT
Completed Early Phase 1 Interventional

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

NCT04616456
View directory record Official record
Conditions
Multiple System Atrophy, Multiple System Atrophy, Cerebellar Variant, Multiple System Atrophy, Parkinson Variant (Disorder), Multiple System Atrophy (MSA) With Orthostatic Hypotension
Interventions
[F-18]PBR06, Verdiperstat
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Jul 22, 2026, 6:40 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

NCT05923866
View directory record Official record
Conditions
Multiple System Atrophy (MSA)
Interventions
ONO-2808, Placebo
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
30 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
30
States / cities
Fountain Valley, California • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 6:40 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies

NCT07640555
View directory record Official record
Conditions
Multiple System Atrophy (MSA), Healthy Adult, Parkinson Disease
Interventions
[¹⁸F]MODAG-009 PET imaging
Drug
Lead sponsor
MODAG GmbH
Industry
Eligibility
50 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 6:40 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

NCT01927055
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease, Multiple Systems Atrophy, Pure Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
New York, New York • Charlotte, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Jul 22, 2026, 6:40 PM EDT
Recruiting No phase listed Observational

Modifiable Variables in Parkinsonism (MVP)

NCT02194816
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, Shy-Drager Syndrome, Corticobasal Degeneration, Dementia With Lewy Bodies, Pick Disease, Olivopontocerebellar Atrophies
Interventions
Not listed
Lead sponsor
Bastyr University
Other
Eligibility
19 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jul 22, 2026, 6:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)

NCT01888185
View directory record Official record
Conditions
Parkinson's Disease (PD), Parkinsonism, Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA)
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 90 Years
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Jul 22, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional

Neurologic Stem Cell Treatment Study

NCT02795052
View directory record Official record
Conditions
Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions
Intravenous and Intranasal BMSC
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 6:40 PM EDT
Completed No phase listed Observational

Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.

NCT02132052
View directory record Official record
Conditions
Essential Tremor, Multiple System Atrophy, Corticobasal Degeneration, Supranuclear Palsy, Progressive, Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Jul 22, 2026, 6:40 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Mesenchymal Stem Cell Therapy in Multiple System Atrophy

NCT02315027
View directory record Official record
Conditions
MSA
Interventions
Autologous Mesenchymal Stem Cells
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 22, 2026, 6:40 PM EDT
Active, not recruiting No phase listed Observational

Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

NCT05699460
View directory record Official record
Conditions
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
Interventions
This is an observational study.
Other
Lead sponsor
AskBio Inc
Industry
Eligibility
35 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jul 22, 2026, 6:40 PM EDT
Completed No phase listed Observational

PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)

NCT02035761
View directory record Official record
Conditions
Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy - Cerebellar Subtype (MSA-C)
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Jul 22, 2026, 6:40 PM EDT
Available No phase listed Expanded access

"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."

NCT07238062
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 85 Years
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 22, 2026, 6:40 PM EDT
Enrolling by invitation No phase listed Observational

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

NCT04680130
View directory record Official record
Conditions
PSP, CBD, PCA, LPA, Semantic Dementia, Semantic Aphasia, Behavioral Variant of Frontotemporal Dementia, FTD, PPA, Apraxia of Speech, MSA - Multiple System Atrophy, Parkinson Disease
Interventions
C-11 PiB, AV1451 Tau, C-11 ER176
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 22, 2026, 6:40 PM EDT